| 1 |
34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | 2021 |
1 |
| 2 |
31006307 | Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. | 2020 Feb |
2 |
| 3 |
33096322 | The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. | 2020 Nov |
1 |
| 4 |
30877503 | A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance. | 2019 Apr |
1 |
| 5 |
31543464 | Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. | 2019 Oct 14 |
2 |
| 6 |
31826340 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. | 2019 Dec 12 |
3 |
| 7 |
29568367 | The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. | 2018 Mar 2 |
2 |
| 8 |
30137981 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. | 2018 Sep 27 |
2 |
| 9 |
28819281 | Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. | 2017 Dec |
1 |